Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Luminex partners with Abbott for newly cleared xTAG RVP test

This article was originally published in Clinica

Executive Summary

Biological testing specialist Luminex has struck a deal with Abbott's molecular diagnostic business for the worldwide distribution of the former's xTAG respiratory viral panel (RVP). The deal, of which financial details were not revealed, will see Abbott gain semi-exclusive distribution rights to the product in the US, and exclusive rights for non-US markets. The xTAG RVP is based on Luminex's xMAP multiplexing technology and, according to the Austin, Texas-based company, can simultaneously test for twelve viruses and viral subtypes within a few hours after a patient sample is taken. The xTAG received 510(k) clearance from the US FDA in January 2008 (see Clinica No 1289, p 18).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel